News Column

Researchers at National Cancer Institute Release New Data on Immunotherapy (The effects of conjugate and light dose on photo-immunotherapy induced...

July 15, 2014



Researchers at National Cancer Institute Release New Data on Immunotherapy (The effects of conjugate and light dose on photo-immunotherapy induced cytotoxicity)

By a News Reporter-Staff News Editor at Cancer Weekly -- Investigators publish new report on Biotechnology. According to news reporting out of Bethesda, Maryland, by NewsRx editors, research stated, "Photoimmunotherapy (PIT) is a highly cell-selective cancer therapy, which employs monoclonal antibodies conjugated to a potent photosensitizer (mAb-IR700). Once the conjugate has bound to the target cell, exposure to near infrared (NIR) light induces necrosis only in targeted cells with minimal damage to adjacent normal cells in vivo."

Our news journalists obtained a quote from the research from National Cancer Institute, "Herein, we report on the effect of altering mAb-IR700 and light power and dose on effectiveness of PIT. For evaluating cytotoxicity, we employed ATP-dependent bioluminescence imaging using a luciferase-transfected MDA-MB-468luc cell line, which expresses EGFR and luciferase. In in vitro experiments, panitumumab-IR700 (Pan-IR700) concentration was varied in combination with varying NIR light doses administered by an LED at one of three power settings, 100 mA and 400 mA continuous wave and 1733 mA intermittent wave. For in vivo experiments, the MDA-MB-468luc orthotopic breast cancer was treated with varying doses of Pan-IR700 and light. The in vitro cell study demonstrated that PIT induced cytotoxicity depended on light dose, when the conjugate concentration was kept constant. Increasing the dose of Pan-IR700 allowed lowering of the light dose to achieve equal effects thus indicating that for a given level of efficacy, the conjugate concentration multiplied by the light dose was a constant. A similar relationship between conjugate and light dose was observed in vivo."

According to the news editors, the research concluded: "The efficacy of PIT is defined by the product of the number of bound antibody conjugates and the dose of NIR light and can be achieve equally with continuous and pulse wave LED light using different power densities."

For more information on this research see: The effects of conjugate and light dose on photo-immunotherapy induced cytotoxicity. BMC Cancer, 2014;14():1-7. BMC Cancer can be contacted at: Biomed Central Ltd, 236 Grays Inn Rd, Floor 6, London WC1X 8HL, England. (BioMed Central - www.biomedcentral.com/; BMC Cancer - www.biomedcentral.com/bmccancer/)

Our news journalists report that additional information may be obtained by contacting T. Nakajima, National Cancer Institute, Mol Imaging Program, Center Canc Res, National Institutes of Health, Bethesda, MD 20892, United States. Additional authors for this research include K. Sato, H. Hanaoka, R. Watanabe, T. Harada, P.L. Choyke and H. Kobayashi (see also Biotechnology).

Keywords for this news article include: Biotechnology, Bethesda, Maryland, Luciferases, United States, Immunotherapy, Immunomodulation, Enzymes and Coenzymes, North and Central America

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Cancer Weekly


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters